Creating breakthrough treatments with siRNA: Lerna Biopharma's liver regeneration story

siRNA therapeutics represent a transformative advancement in medicine and biotechnology, offering precision, versatility, and potential treatments for a wide range of diseases – with several siRNA-based drugs already available to patients. In this SelectScience webinar, Dr Torsten Wuestefeld, Co-founder and Advisor at Lerna Biopharma and Dr. Si Hui Tan, Vice President of Biology at Lerna Biopharma, will share how they are combining novel biology with proprietary nucleic acid technology and delivery platforms to innovate and accelerate therapeutic development for liver diseases with high unmet needs.

Key learning objectives

• Discover how leveraging siRNA can help deliver breakthrough drugs for diseases with unmet needs
• Learn why siRNA is the modality of choice for pursuing novel biology to generate first-in-class drugs
• Hear about design and synthesis of siRNA molecules
• Learn about developing siRNA drug candidates with technologies and platforms that address the challenges in the siRNA therapeutics development process

Who should attend?

• Those who work within R&D at biotechnology and pharma companies
• Those who work at key research institutes who want to learn about RNA drug development

Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.